Следене
Marina Dobrovolskaia
Marina Dobrovolskaia
Sr.Principal Scientist, Nanotechnology Characterization Lab, NCI, LBR
Потвърден имейл адрес: mail.nih.gov
Заглавие
Позовавания
Позовавания
Година
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy
P Aggarwal, JB Hall, CB McLeland, MA Dobrovolskaia, SE McNeil
Advanced drug delivery reviews 61 (6), 428-437, 2009
20502009
Immunological properties of engineered nanomaterials
MA Dobrovolskaia, SE McNeil
Nature nanotechnology 2 (8), 469-478, 2007
20412007
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution
MA Dobrovolskaia, P Aggarwal, JB Hall, SE McNeil
Molecular pharmaceutics 5 (4), 487-495, 2008
11682008
Minireview: nanoparticles and the immune system
BS Zolnik, Á González-Fernández, N Sadrieh, MA Dobrovolskaia
Endocrinology 151 (2), 458-465, 2010
10172010
Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles
MA Dobrovolskaia, AK Patri, J Zheng, JD Clogston, N Ayub, P Aggarwal, ...
Nanomedicine: Nanotechnology, Biology and Medicine 5 (2), 106-117, 2009
8012009
Toll receptors, CD14, and macrophage activation and deactivation by LPS
MA Dobrovolskaia, SN Vogel
Microbes and Infection 4 (9), 903-914, 2002
7172002
Method for analysis of nanoparticle hemolytic properties in vitro
MA Dobrovolskaia, JD Clogston, BW Neun, JB Hall, AK Patri, SE McNeil
Nano letters 8 (8), 2180-2187, 2008
6282008
Characterization of nanoparticles for therapeutics
JB Hall, MA Dobrovolskaia, AK Patri, SE McNeil
Future Medicine Ltd 2 (6), 789-803, 2007
4852007
Evaluation of nanoparticle immunotoxicity
MA Dobrovolskaia, DR Germolec, JL Weaver
Nature nanotechnology 4 (7), 411-414, 2009
4222009
Induction of in vitro reprogramming by Toll-like receptor (TLR) 2 and TLR4 agonists in murine macrophages: effects of TLR “homotolerance” versus “heterotolerance” on NF-κB …
MA Dobrovolskaia, AE Medvedev, KE Thomas, N Cuesta, V Toshchakov, ...
The Journal of Immunology 170 (1), 508-519, 2003
3892003
Nanoparticles and the blood coagulation system. Part II: safety concerns
AN Ilinskaya, MA Dobrovolskaia
Nanomedicine 8 (6), 969-981, 2013
327*2013
Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions
TJ Anchordoquy, Y Barenholz, D Boraschi, M Chorny, P Decuzzi, ...
ACS nano 11 (1), 12-18, 2017
3102017
Current understanding of interactions between nanoparticles and the immune system
MA Dobrovolskaia, M Shurin, AA Shvedova
Toxicology and applied pharmacology 299, 78-89, 2016
2872016
Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines
MA Dobrovolskaia, SE McNeil
Journal of controlled release 172 (2), 456-466, 2013
2862013
Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice
N Chanda, P Kan, LD Watkinson, R Shukla, A Zambre, TL Carmack, ...
Nanomedicine in Cancer, 753-774, 2017
2842017
Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory
RM Crist, JH Grossman, AK Patri, ST Stern, MA Dobrovolskaia, ...
Integrative Biology 5 (1), 66-73, 2013
2712013
Nanoparticle Size and Surface Charge Determine Effects of PAMAM Dendrimers on Human Platelets in Vitro
MA Dobrovolskaia, AK Patri, J Simak, JB Hall, J Semberova, ...
Molecular pharmaceutics 9 (3), 382-393, 2012
2532012
Identification and avoidance of potential artifacts and misinterpretations in nanomaterial ecotoxicity measurements
EJ Petersen, TB Henry, J Zhao, RI MacCuspie, TL Kirschling, ...
Environmental science & technology 48 (8), 4226-4246, 2014
2482014
Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine
KA Afonin, WW Grabow, FM Walker, E Bindewald, MA Dobrovolskaia, ...
Therapeutic RNA Nanotechnology, 249-284, 2021
2202021
To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives
D Shi, D Beasock, A Fessler, J Szebeni, JY Ljubimova, KA Afonin, ...
Advanced drug delivery reviews 180, 114079, 2022
2062022
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20